DNLI Valuation

Denali Therapeutics Inc

Add to Watchlist

Advanced Chart

15.310

-0.14(-0.906%)1D

Overview
Forecast
Valuation
Earnings

DNLI Relative Valuation

DNLI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNLI is overvalued; if below, it's undervalued.

Historical Valuation

Denali Therapeutics Inc (DNLI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 113.19 is considered Undervalued compared with the five-year average of -14.03. The fair price of Denali Therapeutics Inc (DNLI) is between 47.67 to 56.36 according to relative valuation methord. Compared to the current price of 15.31 USD , Denali Therapeutics Inc is Undervalued By 67.88%.

Relative Value

Fair Zone

47.67-56.36

Current Price：15.31

67.88%

Undervalued

-5.03

Trailing

Forward

-2.57

EV/EBITDA

Denali Therapeutics Inc. (DNLI) has a current EV/EBITDA of -2.57. The 5-year average EV/EBITDA is -10.98. The thresholds are as follows: Strongly Undervalued below -29.58, Undervalued between -29.58 and -20.28, Fairly Valued between -1.68 and -20.28, Overvalued between -1.68 and 7.62, and Strongly Overvalued above 7.62. The current Forward EV/EBITDA of -2.57 falls within the Historic Trend Line -Fairly Valued range.

-2.32

EV/EBIT

Denali Therapeutics Inc. (DNLI) has a current EV/EBIT of -2.32. The 5-year average EV/EBIT is -9.72. The thresholds are as follows: Strongly Undervalued below -27.61, Undervalued between -27.61 and -18.67, Fairly Valued between -0.78 and -18.67, Overvalued between -0.78 and 8.17, and Strongly Overvalued above 8.17. The current Forward EV/EBIT of -2.32 falls within the Historic Trend Line -Fairly Valued range.

113.19

Denali Therapeutics Inc. (DNLI) has a current PS of 113.19. The 5-year average PS is 64.06. The thresholds are as follows: Strongly Undervalued below -16.24, Undervalued between -16.24 and 23.91, Fairly Valued between 104.21 and 23.91, Overvalued between 104.21 and 144.37, and Strongly Overvalued above 144.37. The current Forward PS of 113.19 falls within the Overvalued range.

-8.29

P/OCF

Denali Therapeutics Inc. (DNLI) has a current P/OCF of -8.29. The 5-year average P/OCF is -19.39. The thresholds are as follows: Strongly Undervalued below -56.44, Undervalued between -56.44 and -37.92, Fairly Valued between -0.86 and -37.92, Overvalued between -0.86 and 17.66, and Strongly Overvalued above 17.66. The current Forward P/OCF of -8.29 falls within the Historic Trend Line -Fairly Valued range.

-4.84

P/FCF

Denali Therapeutics Inc. (DNLI) has a current P/FCF of -4.84. The 5-year average P/FCF is -15.74. The thresholds are as follows: Strongly Undervalued below -44.61, Undervalued between -44.61 and -30.17, Fairly Valued between -1.30 and -30.17, Overvalued between -1.30 and 13.13, and Strongly Overvalued above 13.13. The current Forward P/FCF of -4.84 falls within the Historic Trend Line -Fairly Valued range.

Denali Therapeutics Inc (DNLI) has a current Price-to-Book (P/B) ratio of 2.19. Compared to its 3-year average P/B ratio of 2.83 , the current P/B ratio is approximately -22.48% higher. Relative to its 5-year average P/B ratio of 4.09, the current P/B ratio is about -46.36% higher. Denali Therapeutics Inc (DNLI) has a Forward Free Cash Flow (FCF) yield of approximately -16.27%. Compared to its 3-year average FCF yield of -11.64%, the current FCF yield is approximately 39.78% lower. Relative to its 5-year average FCF yield of -6.80% , the current FCF yield is about 139.28% lower.

2.19

P/B

Median3y

2.83

Median5y

4.09

-16.27

FCF Yield

Median3y

-11.64

Median5y

-6.80

Competitors Valuation Multiple

The average P/S ratio for DNLI's competitors is 1449.18, providing a benchmark for relative valuation. Denali Therapeutics Inc Corp (DNLI) exhibits a P/S ratio of 113.19, which is -92.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DNLI.O

Denali Therapeutics Inc

Apogee Therapeutics Inc

Recursion Pharmaceuticals Inc

Performance Decomposition

Market capitalization of DNLI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DNLI in the past 1 year is driven by Unknown.